Compare Lamb Weston Holdings Inc (LW) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Zoetis Inc — how do they compare? Lamb Weston Holdings Inc trades at $47.87 (market cap $6.81B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.4× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Zoetis Inc for 70 Days on average.
| LW | ZTS | |
|---|---|---|
Market Cap | $6.81B | $30.20B |
Volume | 4,638,686 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $147.53 |
52-Week Low | $38.48 | $69.09 |
Typical Hold Time | 66 Days | 70 Days |
Enterprise Value | $10.61B | $37.76B |
Dividend Yield | 3.07% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $49.46, up 2.85% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 27.03. Recent news highlights cost-saving initiatives and anticipation for Q1 2026 earnings, while analyst consensus leans toward a hold with a $53.71 price target, suggesting modest upside from current levels.
Outlook remains cautiously optimistic given earnings momentum and operational improvements, but risks include margin pressure from rising costs and competitive threats. The stock's valuation appears fair relative to peers, with potential for growth if margin recovery continues, though investor confidence hinges on upcoming earnings results and execution of strategic initiatives.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
